

Travere Therapeutics, Inc. Nominating / Corporate Governance Committee Charter

*The following Charter was
adopted by the
Board of Directors of Travere Therapeutics, Inc.
on December 9, 2016
as amended on March 6, 2024*

I. Purpose.

The purpose of the Nominating / Corporate Governance Committee (the “Committee”) of the Board of Directors (the “Board”) of Travere Therapeutics, Inc. (the “Company”) is to provide assistance to the Board in fulfilling its responsibility for Board nominations and composition, corporate governance matters and responsibilities in accordance with the Company’s Corporate Governance Guidelines attached as **Exhibit A**.

II. Structure.

A. Membership

The Committee consists of not less than three independent directors, each of whom shall qualify as independent under the NASDAQ listing requirements.

The members of the Committee shall be appointed by the Board. Unless a Chair of the Committee is designated by the Board, the Committee may designate a Chair by a majority vote of the full Committee membership.

B. Rules of Procedure

The Committee may determine its own rules of procedure with respect to the call, place, time, and frequency of its meetings. In the absence of such rules, the Committee will meet at the call of its Chair as appropriate to accomplish the purposes of the Committee, but it is anticipated that the Committee will meet at least twice each calendar year. Notice of meetings of the Committee shall be given as provided in the bylaws of the Company.

C. Committee Secretary

The Secretary of the Company will act as Secretary of the Committee and will attend all meetings; keep minutes of the Committee's proceedings; advise members of all meetings called; arrange with the Chair of the Committee or other convening

authority for preparation and distribution of the agenda and supporting material for each meeting; at the direction of the Chair of the Committee, make the necessary logistical arrangements for each meeting; and carry out other functions as may be assigned from time to time by the Committee. In the event that the Chair of the Committee believes that it is inappropriate for the Secretary of the Company to attend any meeting(s) or portion(s) thereof, the Chair shall appoint a member of the Committee to act as Secretary for such meeting(s) or portion(s) thereof.

D. Quorum

A majority of the members of the Committee will constitute a quorum for the transaction of business.

E. Minutes and Reports.

The Committee shall maintain written minutes or other records of its meetings and activities. Minutes of each meeting of the Committee shall be distributed to each member of the Committee and other members of the Board. The Secretary of the Company shall retain the original signed minutes for filing with the corporate records of the Company.

The Chair shall report to the Board following meetings of the Committee and as otherwise requested by the Chair of the Board.

III. Matters Relating to the Board of Directors.

- A. In consultation with Company senior management, the Committee will review the qualifications of candidates for the Board from whatever sources received.
- B. The Committee, in consultation with Company senior management, may develop guidelines for the composition of the Board. It may include in those guidelines recommendations concerning:
 - 1. Ideal size;
 - 2. The mix of inside/outside directors;
 - 3. Appropriate consideration of diversity;
 - 4. Avoidance of potential conflicts of interest;
 - 5. The scope of geographic representation; and

6. The priority to be given to candidate positions, i.e., CEO or equivalent, etc.
- C. On an annual basis the Committee will evaluate the experience, qualifications, attributes and skills of each of the members of the Board in light of the Company's business and structure to conclude that each such person should continue to serve as a Director. The Committee annually will review with the Board the skills and characteristics required of the members in the context of the then current membership of the Board.
- D. When vacancies on the Board occur between Annual Meetings of Stockholders, the Committee will consult with Company senior management and consider the size of the Board to determine if a replacement is then appropriate and make a recommendation to the Board.
- E. The Committee annually will formally review and assess (assisted by outside consultants if the Committee so desires) the Board's performance and review its findings with the Board. In addition, each individual Director will be periodically reviewed by the Committee for compliance with the Director Qualifications set forth in this charter. In connection with the review of the performance of the Board and individual Directors, each Director shall have the opportunity to provide comments and recommendations.
- F. The Committee will consider the diversity of the Board when evaluating candidates for election or re-election to the Board. It is the Committee's policy to have a diversity of skills, professional experience, education, associations, achievements, training, points of view and individual qualities and attributes represented on the Board. The Committee also considers and endeavors to reflect other aspects of diversity, including but not limited to gender, ethnicity, sexual orientation and race.
- G. The Committee annually will consult each incumbent director whose term expires at the next Annual Meeting of Stockholders to determine if the director desires to seek reelection. The Committee will determine whether all nominees meet the Director Qualifications set forth in this Charter and determine if incumbents are to be nominated for reelection.

The Committee annually will submit the slate of director candidates to be proposed for election by the stockholders at the Annual Meeting of Stockholders to the Board for approval.

- H. From time to time as deemed appropriate, the Committee will review the Company's Corporate Governance Guidelines and may from time to time recommend amendments thereto to the Board.

IV. Succession Planning.

In consultation with the Company's Chief Executive Officer, the Committee will review succession planning relating to the Company's Chief Executive Officer as well as other key members of Company senior management.

V. Committees.

On an annual basis the Committee will review the compliance of each committee of the Board with the Company's committee structure, size and composition rules including whether the committee has held the required number of meetings and provided reports to the Board. The Committee will recommend changes to the composition of the committees as appropriate. In addition, on an annual basis the Committee will review the performance of all of the committees.

VI. Stockholder Matters.

The Committee will periodically review the Company's certificate of incorporation and bylaws and make recommendations to the Board with the objective of promoting good corporate governance. The Committee will also review the procedures and communication plans for stockholder meetings to ensure that the rights of stockholders are protected and that required information concerning the Company is adequately presented.

VII. ESG Matters.

The Committee will periodically review environmental, social and governance ("ESG") matters pertaining to the Company, including ESG policies and initiatives, and will assist the Board in coordinating ESG related activities among the other committees of the Board.

VIII. Cybersecurity.

The Committee will periodically review and discuss with the appropriate members of the Company's management material risks relating to data privacy, technology and information security, including cybersecurity, threats and back-up of information systems and the Company's processes for assessing, identifying, and managing such risks, as well as the Company's internal controls and disclosure controls and procedures relating to cybersecurity incidents.

IX. Responsibilities of the Committee.

The Committee will review the Company's compliance with the Company's Corporate Governance Guidelines. The Committee, through its Chair, will present the Committee's findings to the Board for its consideration and periodically review with the Board the Committee's activities and determinations.

X. Resolutions and Written Consents.

All proposed resolutions will be prepared by internal or external counsel and discussed and voted upon at the meetings or adopted by unanimous written consent.

XI. Additional Authority.

The Committee shall have the authority, at its discretion, to call upon the Chair of the Board to provide internal assistance from officers and other employees of the Company and its subsidiaries as may be appropriate to fulfill its duties and responsibilities. The Committee shall be authorized to access such internal and external resources as the Committee deems necessary or appropriate to fulfill its defined responsibilities, including engagement of independent counsel, consultants and other professional advisors, as well as authority to retain and terminate executive search firms to help identify Director candidates. The Committee shall have sole authority to approve fees, costs and other terms of engagement of such outside resources. The Committee shall have the authority to perform such other functions, and shall have such powers, as may be necessary or appropriate in the efficient and lawful discharge of its responsibilities hereunder.

XII. Evaluation of Performance of Committee.

The Committee shall evaluate its own performance on an annual basis, including its compliance with this charter. The Committee shall conduct such evaluation and review in such manner as it deems appropriate.

The Committee shall review and reassess the Committee's charter at least annually and submit any recommended changes to the Board for its consideration.

XIII. Disclosure of Charter.

This Charter will be made available on the Company's website and to any stockholder who otherwise requests a copy. The Company's Annual Report to Stockholders shall state the foregoing.

Exhibit A

Travere Therapeutics, Inc.
Corporate Governance Guidelines

I. Purpose.

The purpose of these guidelines is to provide assistance to the Board of Directors (the “Board”) of Travere Therapeutics, Inc. (the “Company”) in managing Board composition, representation, function and performance.

II. Board Membership and Leadership.

A. Chair of the Board and Chief Executive Officer.

It is the policy of the Board to separate the offices of Chair of the Board and Chief Executive Officer.

When Directors meet without the presence of the Chair of the Board, the Directors should select the Chair of the meeting.

B. Number of Directors.

The size of the Board should reflect the requirements of the Board’s committees and the availability of qualified individuals and accordingly the size of the Board may be changed as necessary in accordance with the provisions of the Company’s bylaws.

C. Director Qualifications.

Members of the Board and Nominees for election to the Board will have the following qualifications:

1. Be less than 70 years of age at the time of first election;
2. Be a member of not more than four other public company boards of directors; if a member of the Audit Committee, serve as chair of not more than two other audit committees of public companies; if a named executive officer of a public company, serve on not more than two other public company boards of directors.
3. Have the diversity of skills, professional experience, education, associations, achievements, training, points of view and individual qualities and attributes appropriate for representation on the Board;

4. Have no affiliation with a competitor or have, or appear to have, a conflict of interest that would impair their ability to fulfill the responsibilities of a Director and represent the stockholders;
5. Have high quality personal and professional references;
6. Attend at least 75% of the scheduled Board meetings and provide meaningful participation;
7. Commitment to adhere to the Company's policies, including but not limited to the Company's Insider Trading Policy, Code of Business Conduct and Ethics and Corporate Disclosure Policy;
8. Commitment to, in the event the Nominating / Corporate Governance Committee determines the Director does not meet these qualifications, immediately resign from the Board or not stand for re-election, in either case to the extent requested by the Nominating / Corporate Governance Committee.

D. Mix of Independent and Non-Independent Directors.

The Board will be comprised of a majority of independent Directors. The Board believes that, generally, there should be no more than one officer Director on the Board, who should be the Chief Executive Officer.

An independent Director is a Director who meets the independence requirements of The Nasdaq Stock Market. Compliance with the definition of independent Director should be reviewed annually by the Nominating / Corporate Governance Committee.

E. Former Officers.

Board membership by former Company officers is a matter to be decided by the Board in each individual instance. When an officer who is also a Director resigns as an officer of the Company, he or she should submit to the Chief Executive Officer and Chair of the Board a written offer to resign from the Board which resignation will only be effective if and when accepted by the Board.

III. Selection of Directors.

The Nominating / Corporate Governance Committee annually should review with the Board the appropriate skills and characteristics required of Board members in the context of the then current membership of the Board.

The Nominating / Corporate Governance Committee will be responsible for nominating all Directors for election either by stockholders at an annual or special meeting or by the Board in the case of Directors who are elected to fill vacancies in accordance with the Company's bylaws. The Nominating / Corporate Governance Committee, in consultation with the Chair of the Board, should review Director nominations and may engage consultants to assist it in identifying and screening potential candidates.

Every new Director should receive an orientation and education program to acquaint the Director with the history, operation and management of the Company and the business conditions and regulatory regime to which it is subject.

IV. Director Resignation Policy.

Although according to the Company's bylaws all elections are determined by a plurality of the votes cast, it is the Company's policy that any nominee for Director in an uncontested election who does not receive a majority of the votes cast (i.e., receives a greater number of votes "withheld" from or "against" his or her election than votes "for" in such election) shall submit his or her offer of resignation for consideration by the Nominating / Corporate Governance Committee. The Nominating / Corporate Governance Committee shall consider all of the relevant facts and circumstances and recommend to the Board the action to be taken with respect to such offer of resignation. The Board will then act on the Nominating / Corporate Governance Committee's recommendation. Promptly following the Board's decision, the Company will disclose that decision and an explanation of such decision in a filing with the Securities and Exchange Commission and a press release.

V. Changes in Responsibilities.

Directors have an obligation to promptly notify the Chair of the Nominating / Corporate Governance Committee in writing when (or to the extent practicable, prior to) (i) they first stand for election to any public or private board of directors, chair of any audit committee or member of any compensation committee, (ii) they first become affiliated (as an advisor, consultant or otherwise) with any public or private organization within (or directly affiliated with) the pharmaceutical industry that is a competitor of the Company or where there is a potential conflict of interest and/or (iii) they experience a substantial change in their employment responsibilities (including but not limited to any change in title or employer) or affiliations, in each case above, other than those held when they were last elected to the Board.

The Board does not believe that Directors who retire or otherwise change employment should necessarily leave the Board. However, there should be an opportunity for the Board, through the Nominating / Corporate Governance Committee, to review the continued appropriateness of Board membership under changed circumstances.

VI. Board Committee Structure and Function.

A. Committees.

The Board currently maintains Audit, Compensation, and Nominating / Corporate Governance, and Science and Medical Technology Committees operating under charters approved by the Board. From time to time, the Board may find it desirable to form new committees or combine or disband existing committees, consistent with legal and other obligations.

Only independent Directors should serve on the Audit, Compensation and Nominating / Corporate Governance Committees.

B. Assignment and Rotation of Committee Members.

The Board shall appoint the members of committees of the Board, taking into account the desires and expertise of individual Directors and the suggestions of the Chair of the Board. Directors may indicate their committee preferences from time to time to the Chair of the Board.

The Board believes that members of committees of the Board should be periodically rotated. The Board believes, however, that such rotation should not be mandatory since, from time to time, there may be compelling reasons to lengthen or shorten an individual Director's committee membership.

C. Committee Meetings.

The chair of each committee of the Board, in consultation with the committee's members, should determine the frequency and length of the meetings of the committee, in compliance with the applicable committee charter and regulatory requirements.

The chair of each committee of the Board in consultation with the Company senior management should develop the committee's agenda. Each member of a committee is free to suggest the inclusion of items on the agenda and to raise at any meeting subjects that are not on the agenda.

The Chair of the Board and Chief Executive Officer are encouraged to attend all Committee meetings as nonvoting participants to ensure that they each have full information regarding the actions by, and co-ordination of, the Committees, except where such attendance (full or partial) would be inappropriate (e.g., in the case of the Chief Executive Officer, when the Compensation Committee is deciding on the Chief Executive Officer's compensation).

VII. Board Meetings.

A. Selection of Agenda Items.

The Chair of the Board together with the Company's Chief Executive Officer should establish the agenda for each meeting of the Board. Each Director generally is free to suggest the inclusion of items on the agenda and to raise at any meeting subjects that are not on the agenda.

B. Advance Distribution of Board Materials.

Information and data that are important to the understanding of the business to be conducted at a meeting of the Board should be distributed in writing to the Board in advance of the meeting. These materials should highlight significant developments not previously presented and be as brief as consistent with providing the appropriate information.

C. Regular Attendance of Non-Directors.

The Chief Financial Officer and General Counsel should regularly attend meetings of the Board. Such additional officers as are appropriate for informed discussion and response to agenda items should also attend.

D. Executive Sessions of Independent Directors.

At least two times during the year, executive sessions of the independent members of the Board will be held to review matters concerning the relationship of the Board with the non-independent Directors and other members of the corporation's management and such other matters as the participating Directors may deem appropriate.

VIII. Other Board Communications and Activities.

A. Strategic and Financial Planning.

At least once each year the Board should review management's long-term strategic and financial plan and management's expectations regarding the strategic and financial issues that the Company may face in the foreseeable future.

B. Board Access to Senior Management, Independent Auditors and Counsel.

Members of the Board shall have complete access to the Company's senior management and independent auditors, and direct access to other employees,

which should normally be coordinated with senior management. The Board also shall have complete access to counsel of its choice with respect to any issue relating to the discharge of the duties of Directors.

It is assumed that members of the Board will use judgment to be sure that contacts with management are not distracting to the Company's business operations of and will advise the Chair of the Board of any substantive contacts. Furthermore, the Board encourages management to invite to Board meetings members of management who can provide additional insight into the items to be discussed or who senior management believes to have sufficient executive potential that they should be given exposure to the Board.

C. Board Compensation Review.

The Compensation Committee of the Board annually shall review with the Board the compensation of non-employee directors in other comparable companies. Changes in non-employee director compensation, if any, also shall be reviewed and presented by the Compensation Committee.

D. Assessment of Board Performance.

The Nominating / Corporate Governance Committee of the Board annually shall formally review and assess (assisted by outside consultants if the Committee so desires) the Board's performance. The assessment also should be of the Board's contribution as a whole and specifically review areas in which the Board or management believes a better contribution could be made. The purpose of the review is to increase the effectiveness of the Board and it shall be reviewed with the Board.

E. Evaluation of the Chief Executive Officer and Employee Directors.

The Chair of the Board in consultation with the Chair of the Compensation Committee and considering input from each of the members of the Board, will formally evaluate the Chief Executive Officer on an annual basis. The Chief Executive Officer annually shall formally evaluate all executive officers. These evaluations will be based principally upon objective criteria including business performance, accomplishment of strategic objectives, development of management and other matters relevant to the Company's short term and long-term success and the creation of stockholder value. These evaluations shall be considered by the Compensation Committee in its deliberations with respect to the compensation of these officers.

F. Board Interaction with Institutional Investors, Customers, Media and Others.

The Chief Executive Officer and the Company's Investor Relations Department speak for the Company. Nevertheless, individual Directors may, from time to time, be called upon to meet or otherwise communicate with the Company's various constituencies. It is expected that, absent unusual circumstances, Directors would do so only at the request of management and will advise the Chair of the Board of any substantive communications.

IX. Administration

A. Review and Amendments.

The Nominating / Corporate Governance Committee of the Board should assume general responsibility for developing the Company's approach to corporate governance issues and periodically review compliance with these guidelines. It also shall annually review these guidelines and, subject to the approval of the Board, may amend them from time to time. On matters of corporate governance, independent Directors should make all decisions.

B. Availability to Stockholders.

The Corporate Governance Guidelines shall be made available on the Company's website and to any stockholder who otherwise requests a copy. The Company's Annual Report to Stockholders will state the foregoing.